A women’s formula needs a biological argument.
We reject formulas that promise “hormone balance” without explaining what is being supported. Our approach starts with insulin-linked signaling and ovarian physiology, keeps myo-inositol dominant, assigns D-chiro-inositol a precise supporting role, and adds PQQ for the cellular-energy layer behind daily function.
This is why our formula is not a generic inositol blend. Every active has a disclosed identity, amount, and assignment—and the 40:1 relationship can be calculated directly from the label.
Metabolism and ovarian function do not operate separately.
Metabolic signaling
Insulin-linked signaling helps cells respond to nutrient availability. Myo- and D-chiro-inositol participate in related second-messenger systems.
Ovarian environment
Follicular development, steroid signaling, and ovulatory rhythm exist inside the broader metabolic environment.
Cellular energy
Ovarian and endocrine tissues are active tissues. Their function depends on the same mitochondrial energy systems used throughout the body.
That connection matters in conditions such as PCOS, which is heterogeneous and can involve reproductive, metabolic, dermatologic, and psychological features. It cannot be reduced to one laboratory value or solved by one supplement.1
Our ratio is a choice, not a coincidence.
Myo-inositol is the predominant form in the body and the anchor of our women’s formula. D-chiro-inositol is produced from MI and contributes to related but distinct signaling contexts. We do not treat DCI as a “stronger” version of MI or increase it simply to make the label look more novel.
A small clinical study comparing seven MI/DCI ratios reported the strongest results in its 40:1 group.5 We take that as a meaningful formulation signal, alongside the physiological rationale for keeping MI dominant. That is why ESTHELIV chooses 40:1.
We consider 40:1 the most coherent ratio for our formula because it protects the dominant role of myo-inositol while giving D-chiro-inositol a defined, transparent place. The ratio is only credible because both milligram amounts are disclosed.
Three ingredients, three assignments.
Myo-Inositol
1,000 mgThe dominant inositol form and foundation of the formula’s metabolic and ovarian-wellness positioning.
Explore MI →PrecisionD-Chiro-Inositol
25 mgA complementary isomer used at one part for every 40 parts of myo-inositol.
Explore DCI →Cellular energyPureQQ® PQQ
10 mgA distinct mitochondrial-signaling ingredient that extends the formula beyond inositol-only support.
Explore PQQ →Traditional ovarian formulas often stop at hormone or insulin language. We go deeper. PQQ adds a mitochondrial dimension linked to cellular-energy and renewal signaling, giving the formula an energy architecture as well as an inositol architecture.6
The goal changes. The biology stays connected.
Monthly rhythm
Cycle regularity can reflect metabolic, endocrine, stress, nutritional, and reproductive factors—not one universal cause.
Metabolic wellness
Inositol research often centers on insulin-linked measures, but lifestyle and medical context remain part of the system.
Fertility planning
Ingredient decisions should fit the person’s diagnosis, medicines, fertility treatment, and clinician-guided plan.
Long-term resilience
Muscle, bone, sleep, nutrient status, and cellular energy become increasingly important across adult life stages.
Women’s health should be supported confidently, not simplified. New cycle changes, fertility concerns, pregnancy, severe symptoms, or suspected PCOS deserve individualized medical evaluation.
Promising enough to formulate. Not finished enough to stop asking questions.
Trials and comparative studies have reported favorable changes in selected metabolic, endocrine, or reproductive measures with myo-inositol, D-chiro-inositol, or combinations.34 The direction supports serious interest in the category.
At the same time, the systematic review informing the 2023 international PCOS guideline judged many clinical benefits limited or uncertain because studies vary in formulation, dose, comparator, population, and outcome reporting.2 Our response is not neutrality: it is transparent judgment. We choose MI-led 40:1, disclose the dose, and build beyond the ratio with PQQ.
Women’s Health FAQs
What does a 40:1 inositol ratio mean?+
It means 40 parts myo-inositol for every one part D-chiro-inositol. In Optimal Ovarian Health, 1,000 mg MI divided by 25 mg DCI equals 40:1.
Why is myo-inositol the dominant form?+
Myo-inositol is the predominant inositol form in the body and has the broader research base in women's metabolic and reproductive wellness. We use DCI as a complementary form rather than the lead.
Does the ratio matter more than the dose?+
No. A ratio only describes proportion. Both milligram amounts and the complete daily serving must be disclosed.
Why add PQQ to an ovarian formula?+
PQQ adds a cellular-energy and mitochondrial-signaling layer. It has a different assignment from the two inositol forms and is not included to change the 40:1 ratio.
Is this page only for women with PCOS?+
No. The page explains the biology and formula architecture. Anyone with PCOS symptoms, irregular cycles, fertility concerns, or a diagnosed endocrine condition should seek individualized care.
References
- 2023 International Evidence-based Guideline for PCOSTeede HJ, et al. Human Reproduction. 2023;38(9):1655–1679.
- Inositol for PCOS: systematic review informing the 2023 guidelineFitz V, et al. Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630–1655.
- Metabolic and hormonal effects of myo-inositol: double-blind trialCostantino D, et al. European Review for Medical and Pharmacological Sciences. 2009;13(2):105–110.
- Comparison of myo-inositol and D-chiro-inositolPizzo A, et al. Gynecological Endocrinology. 2014;30(3):205–208.
- Comparison of seven MI/DCI ratiosNordio M, et al. European Review for Medical and Pharmacological Sciences. 2019;23(12):5512–5521.
- PQQ stimulates mitochondrial biogenesis through CREB and PGC-1αChowanadisai W, et al. Journal of Biological Chemistry. 2010;285(1):142–152.